Overview

Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this study is to assess the relative bioavailability of two test tablet formulations of ABT-450 as compared to the ABT-450 hard gelatin capsule formulation as a reference.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Abbott
Treatments:
Ritonavir
Criteria
Inclusion Criteria

- Overall healthy subjects

- Non-childbearing potential females included

Exclusion Criteria

- Positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab

- Clinically significant cardiovascular, respiratory (except mild asthma), renal,
gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical
illness or psychiatric disorder

- Use of tobacco or nicotine-containing products with the 6-month period prior to study
drug administration

- Abnormal screening laboratory results that are considered clinically significant by
the investigator

- Pregnant or breastfeeding female; requirement for any OTC and/or prescription
medication, vitamins and/or herbal supplements on a regular basis

- Previous exposure to ABT-450